

# D-Serine inhibits serine palmitoyltransferase, the enzyme catalyzing the initial step of sphingolipid biosynthesis

Kentaro Hanada<sup>a,b,\*</sup>, Tomoko Hara<sup>a,b</sup>, Masahiro Nishijima<sup>a</sup>

<sup>a</sup>Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

<sup>b</sup>CREST, Japan Science and Technology Corporation, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan

Received 30 March 2000; received in revised form 28 April 2000

Edited by Shozo Yamamoto

**Abstract** Serine palmitoyltransferase (SPT), responsible for the initial step of sphingolipid biosynthesis, catalyzes condensation of palmitoyl coenzyme A and L-serine to produce 3-ketodihydrosphingosine (KDS). For determination of the stereochemical specificity of the amino acid substrate, a competition analysis of the production of [<sup>3</sup>H]KDS from L-[<sup>3</sup>H]serine was performed using purified SPT. D-Serine inhibited [<sup>3</sup>H]KDS production as effectively as non-radioactive L-serine, whereas neither D-alanine nor D-threonine showed any significant effect. Incubation of purified SPT with [palmitoyl 1-<sup>14</sup>C]palmitoyl coenzyme A and D-serine did not produce [<sup>14</sup>C]KDS, while the control incubation with L-serine did. These results suggest that D-serine competes with L-serine for the amino acid recognition site of SPT, but that D-serine is not utilized by this enzyme to produce KDS.

© 2000 Federation of European Biochemical Societies.

**Key words:** D-Serine; Serine palmitoyltransferase; Sphingolipid

## 1. Introduction

Sphingolipids are ubiquitous constituents of membrane lipids in mammalian cells, and are also distributed widely in other animals, plants, and microbes [1]. Sphingolipid biosynthesis is initiated by condensation of L-serine with palmitoyl coenzyme A (CoA) to generate 3-ketodihydrosphingosine (KDS), which is a reaction catalyzed by serine palmitoyltransferase (SPT), a pyridoxal phosphate-dependent enzyme embedded in the endoplasmic reticulum ([2–4] and references therein). The SPT enzyme consists of two subunits, 53-kDa LCB1 and 63-kDa LCB2, with a 1:1 stoichiometry [4]. The LCB2 subunit, but not the LCB1, has a conserved motif, in which a lysine residue has been speculated to bind to a pyridoxal phosphate group [5–10], although both subunits require expression of the SPT activity [5,6,10–12]. Substrate specificity analysis with a purified enzyme has shown that SPT preferentially uses palmitoyl CoA as the acyl CoA substrate and specifically serine as the amino acid substrate [4].

Recently, D-serine has been demonstrated to exist naturally in the brain [13,14], in which sphingolipids are relatively abundant as compared with other tissues [15,16]. Thus, in the

present study, we examined the stereochemical specificity of the amino acid substrate for SPT, and showed that D-serine is a competitive inhibitor of L-serine in the SPT reaction.

## 2. Materials and methods

### 2.1. Materials

L-Serine, D-alanine, D-threonine, and palmitoyl CoA were purchased from Sigma, and D-serine was from Peptide Institute Inc. (Osaka, Japan). L-[<sup>3</sup>H(G)]serine (20 Ci/mmol) and [palmitoyl 1-<sup>14</sup>C]palmitoyl CoA (55 mCi/mmol) were from American Radiolabeled Chemicals.

### 2.2. Purification of SPT

The LY-B strain is a Chinese hamster ovary (CHO) cell mutant lacking the endogenous LCB1 subunit [11], and LY-B/FHcLCB1 is an LY-B transformant stably expressing a FLAG- and His<sub>6</sub>-peptide tagged version of the hamster LCB1 protein [4]. SPT was purified from LY-B/FHcLCB1 cells, as described previously [4]. In brief, membranes prepared from LY-B/FHcLCB1 cells were solubilized by a non-ionic detergent sucrose monolaurate, and then active SPT was purified from the solubilized membrane fraction to homogeneity by affinity peptide chromatography.

### 2.3. Assay of SPT activity

Purified SPT (25 ng protein) was incubated in 200 µl of a standard SPT reaction buffer (50 mM HEPES–NaOH buffer (pH 7.5) containing 5 mM EDTA, 5 mM dithiothreitol, 50 µM pyridoxal phosphate, 25 µM palmitoyl CoA, and 0.1 mM L-[<sup>3</sup>H(G)]serine (50 mCi/mmol)) at 37°C for 10 min. After stopping the reaction, lipids were extracted and the radioactivity of the [<sup>3</sup>H]KDS that formed was measured, as described previously [2]. Radioactivity extracted from enzyme-minus controls was regarded as a background control.

## 3. Results

### 3.1. D-Serine inhibits SPT

Using assays to determine whether the production of [<sup>3</sup>H]KDS from 0.1 mM L-[<sup>3</sup>H]serine with purified SPT was inhibited by excess amounts of non-radioactive competitors, we have recently shown that neither L-alanine, L-threonine, L-serinamide, D,L-serinol, nor L-serine methylester serves as a strong competitor against the production of [<sup>3</sup>H]KDS, indicating that all of the amino, carboxyl, and hydroxyl groups of L-serine are responsible for the substrate recognition of the enzyme [4]. In the present study, we used a competition assay to examine the stereochemical specificity of the amino acid substrate for SPT activity. When 5 mM D-serine was used as a competitor, [<sup>3</sup>H]KDS formation was inhibited by 90%, similar to the result with 5 mM non-radioactive L-serine (Fig. 1). D-Alanine and D-threonine, however, were ineffective (Fig. 1A). A dose-response analysis determined that a concentration caused 50% inhibition (IC<sub>50</sub>) of D-serine for [<sup>3</sup>H]KDS

\*Corresponding author. Fax: (81)-3-5285 1157.  
E-mail: hanak@nih.go.jp

**Abbreviations:** CoA, coenzyme A; KDS, 3-ketodihydrosphingosine; SPT, serine palmitoyltransferase; CHO, Chinese hamster ovary; IC<sub>50</sub>, the concentration which caused 50% inhibition

production was 0.3 mM, which was almost identical to the  $IC_{50}$  of L-serine (Fig. 1B). This unexpected nature of SPT was not due to a possible partial denaturation of the enzyme during purification, because similar inhibitory effects of D-serine were observed when intact membranes from wild-type CHO-K1 and bovine brain cells were used as enzyme sources (data not shown). This effect of D-serine was also not due to contaminated L-serine, which unavoidably exists in commercially available D-serine to a certain extent, because the level of L-serine in the D-serine reagent used was less than 0.6% (mol/mol) (personal communication from the manufacturer, Peptide Institute Inc.). D-Serine obtained from a different supplier (Sigma) also inhibited SPT activity (data not shown), although the level of L-serine in the D-serine reagent from Sigma was unknown.

To test whether the inhibition mode by D-serine was competitive with L-serine, the influence of D-serine on double reciprocal kinetic plots of KDS formation from L-serine was examined. Compared with plots obtained at various L-serine concentrations in the absence of D-serine, addition of 0.3 mM D-serine to the SPT reaction mixture did not cause any reduction of the apparent  $V_{max}$  value, but caused a change in the slope of the plots (Fig. 1C), suggesting that D-serine inhibited the SPT reaction in a competitive manner to L-serine.




Fig. 1. Effects of D-amino acids on the formation of  $[^3H]$ KDS from L- $[^3H]$ serine. A: Purified SPT (25 ng protein) was incubated in the SPT reaction buffer containing 0.1 mM L- $[^3H]$ serine (50 mCi/mmol) and 5 mM each of the non-radioactive competitors indicated at 37°C for 10 min. The radioactivity of the  $[^3H]$ KDS that formed was measured as described in Section 2. Data from three experiments are shown as the percentage of the mean radioactivity of  $[^3H]$ KDS formed in the absence of the competitors. B: Purified SPT (25 ng protein) was incubated in the SPT reaction buffer containing 0.1 mM L- $[^3H]$ serine (50 mCi/mmol) and various concentrations of non-radioactive D-serine (closed circles) or L-serine (open circles) at 37°C for 10 min. Data are shown as the percentage of radioactivity of  $[^3H]$ KDS formed without addition of non-radioactive serine. C: Purified SPT (25 ng protein) was incubated in the SPT reaction buffer containing various concentrations of L- $[^3H]$ serine in the presence (closed circles) or absence (open circles) of 0.3 mM D-serine at 37°C for 10 min. Data obtained are shown as double reciprocal plots.




Fig. 2. SPT did not produce KDS from palmitoyl CoA and D-serine. Purified SPT (40 ng protein) was incubated in 200  $\mu$ l of 50 mM HEPES-NaOH (pH 7.5) containing 25  $\mu$ M [palmitoyl-1- $^{14}C$ ]palmitoyl CoA (55 mCi/mmol), 50  $\mu$ M pyridoxal phosphate, 5 mM EDTA, and 5 mM dithiothreitol in the presence or absence of 1 mM L- or D-serine at 37°C for 10 min. As an enzyme-minus control, vehicle buffer was added in place of the enzyme. Radioactive lipids were then extracted and separated by TLC with a solvent of chloroform/methanol/2 *N* ammonia (80/20/2, by volume). Radioactive lipids on the TLC plate were visualized by image analysis. The mobility of the standard  $[^{14}C]$ KDS, which was formed by the SPT reaction with L- $[^{14}C]$ serine (158 mCi/mmol; Amersham Pharmacia Biotech) is shown by the arrow. Lanes 1 and 2, 1 mM L-serine and D-serine, respectively, without the enzyme; lanes 3–5, no serine, 1 mM L-serine, and 1 mM D-serine, respectively, with purified SPT.

### 3.2. D-Serine is not a productive substrate of SPT

To address the question whether D-serine serves as a substrate of SPT to produce KDS, purified SPT was incubated with 25  $\mu$ M [palmitoyl 1- $^{14}C$ ]palmitoyl CoA in the presence of 1 mM D- or L-serine, and radioactive lipid products of the reaction were analyzed by TLC. When incubated with D-serine, the radioactive lipid patterns were the same as those of the negative control without any serine (Fig. 2, lane 3 vs. 5), although a radioactive compound co-migrating with standard KDS was produced when incubated with L-serine (Fig. 2, lane 4). These results demonstrated that D-serine is not a productive substrate of SPT.

## 4. Discussion

In the course of the competition assay of the SPT reaction with the purified enzyme, we unexpectedly found that D-serine inhibited  $[^3H]$ KDS formation with an  $IC_{50}$  of  $\sim 0.3$  mM (Fig. 1B), which is a value similar to the  $K_m$  of L-serine for the SPT reaction [4]. The mode of inhibition for  $[^3H]$ KDS formation by D-serine appears to be competition with L- $[^3H]$ serine (Fig. 1C). There was a slight possibility that the inhibition of  $[^3H]$ KDS production from L- $[^3H]$ serine by D-serine was due to a simple dilution effect of non-radioactive L-serine, which might have been produced by isomerization of D-serine during the assay. However, this possibility was eliminated by the observation that incubation of purified SPT with D-serine and radioactive palmitoyl CoA produced no KDS (Fig. 2). These results suggest that D-serine competes with L-serine




Fig. 3. A postulated mechanism of inhibition of the SPT reaction by D-serine. The Lys residue bound to pyridoxal phosphate in hamster SPT is predicted to be Lys<sup>377</sup> in the LCB2 subunit [10].

for the amino acid recognition site of SPT, although D-serine is not utilized by SPT to produce KDS.

Recognition of L-serine by SPT is likely to involve Schiff-base formation between the amino acid substrate and a pyridoxal phosphate-group in the enzyme [17,18]. Binding of both enantiomers of a compound to one enzyme is exceptional, but not inconceivable for pyridoxal phosphate-dependent enzymes. For example, serine racemase, a pyridoxal phosphate-dependent enzyme, recognizes both L- and D-serine, and catalyzes the conversion of L-serine to D-serine and vice versa [19]. Thus, the SPT enzyme is presumably able to form Schiff-base complexes with both enantiomers of serine, although in the postulated next reaction, substitution of the  $\alpha$ -hydrogen atom of serine by the palmitoyl group of palmitoyl CoA [17,18], may proceed in the Schiff-base complex with L-serine, but not D-serine (Fig. 3).

Sphingolipids synthesized via SPT reaction in intact cells can be metabolically labeled by incubation of the cells with radioactive L-serine [4,10]. Addition of an excess amount (10 mM) of non-radioactive L-serine to a metabolic labeling medium containing L-[<sup>14</sup>C]serine inhibited formation of radioactive sphingolipids in CHO cells almost completely, whereas 10 mM D-serine caused only slight inhibition (our unpublished observation), probably due to the inefficient uptake of D-serine into cells. However, it has recently been revealed that substantial quantities of D-serine are present in discrete areas of the brain [13,14]. In such specific cell types, D-serine is

synthesized from L-serine by serine racemase, a cytosolic enzyme [19,20]. Therefore, our finding that D-serine inhibits *in vitro* SPT activity raises the previously unrecognized possibility that D-serine affects sphingolipid synthesis in certain cell types enriched by it, although further studies are needed to elucidate the physiological relevance of the inhibition of the SPT reaction by D-serine.

**Acknowledgements:** This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science, Culture, and Sports in Japan, and the Special Coordination Fund for Promoting Science and Technology from the Science and Technology Agency of Japan.

## References

- [1] Karlsson, K.-A. (1970) *Chem. Phys. Lipids* 5, 6–43.
- [2] Williams, R.D., Wang, E. and Merrill Jr., A.H. (1984) *Arch. Biochem. Biophys.* 228, 282–291.
- [3] Mandon, E.C., Ehses, I., Rother, J., van Echten, G. and Sandhoff, K. (1992) *J. Biol. Chem.* 267, 11144–11148.
- [4] Hanada, K., Hara, T. and Nishijima, M. (2000) *J. Biol. Chem.* 275, 8409–8415.
- [5] Buede, R., Rinker-Schaffer, C., Pinto, W.J., Lester, R.L. and Dickson, R.C. (1991) *J. Bacteriol.* 173, 4325–4332.
- [6] Nagiec, M.M., Baltisberger, J.A., Wells, G.B., Lester, R.L. and Dickson, R.C. (1994) *Proc. Natl. Acad. Sci. USA* 91, 7899–7902.
- [7] Zhao, C., Beeler, T. and Dunn, T. (1994) *J. Biol. Chem.* 269, 21480–21488.
- [8] Nagiec, M.M., Lester, R.L. and Dickson, R.C. (1996) *Gene* 177, 237–241.
- [9] Weiss, B. and Stoffel, W. (1997) *Eur. J. Biochem.* 249, 239–247.
- [10] Hanada, K., Hara, T., Nishijima, M., Kuge, O., Dickson, R.C. and Nagiec, M.M. (1997) *J. Biol. Chem.* 272, 32108–32114.
- [11] Hanada, K., Hara, T., Fukasawa, M., Yamaji, A., Umeda, M. and Nishijima, M. (1998) *J. Biol. Chem.* 273, 33787–33794.
- [12] Gable, K., Slife, H., Bacikova, D., Monaghan, E. and Dunn, T.M. (2000) *J. Biol. Chem.* 275, 7597–7603.
- [13] Hashimoto, A., Nishikawa, T., Hayashi, T., Fujii, N., Harada, K., Oka, T. and Takahashi, K. (1992) *FEBS Lett.* 296, 33–36.
- [14] Nagata, Y. (1992) *Experientia* 48, 753–755.
- [15] White, D.A. (1973) in: *Form and Function of Phospholipids* (Ansell, G.B., Hawthorne, J.N., and Dawson, R.M.C., Eds.), pp. 441–482, Elsevier Science, Amsterdam.
- [16] Ledeen, R.W. (1978) *J. Supramol. Struct.* 8, 437–453.
- [17] Braun, P.E. and Snell, E.E. (1968) *J. Biol. Chem.* 243, 3775–3783.
- [18] Krisnangkura, K. and Sweeley, C.C. (1976) *J. Biol. Chem.* 251, 1597–1602.
- [19] Wolosker, H., Sheth, K.N., Takahashi, M., Mothet, J.-P., Brady Jr., R.O., Ferris, C.D. and Snyder, S.H. (1999) *Proc. Natl. Acad. Sci. USA* 96, 721–725.
- [20] Wolosker, H., Blackshaw, S. and Snyder, S.H. (1999) *Proc. Natl. Acad. Sci. USA* 96, 13409–13414.